Zynerba provides progress report on its potential Fragile X syndrome therapy

Zynerba Pharmaceuticals, a developer of synthetic and transdermal cannabinoid therapies for rare neuropsychiatric disorders, said Thursday it expects to begin a "pivotal" late-stage clinical trial of its experimental Fragile X syndrome therapy Zygel late next year. The leaders of the 13-year-old Devon company said they believe positive results from the trial, to confirm previous study results, would be sufficient to support the submission of a new drug application for Zygel to treat Fragile X. Zynerba's…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news